Charles River Laboratories International, Inc.
Location
Massachusetts
Founded
1947-02-28
Website
Risk Signals
1069 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research, Testing Laboratories), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Charles River Laboratories International, Inc.
Live alerts from global media, monitored by Business Radar
2025-01-21 (defenseworld.net)
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Assenagon Asset Management S.A. -
Read Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Assenagon Asset Management S.A. at Defense World
Read more
2024-11-25 (marketbeat.com)
Horizon Kinetics Asset Management LLC Sells 45,619 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
Horizon Kinetics Asset Management LLC decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 28.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1
Read more
2024-10-12 (marketbeat.com)
MADDEN SECURITIES Corp Sells 8,625 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
MADDEN SECURITIES Corp lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 59.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,830 shares of the medical resea
Read more
2024-09-28 (defenseworld.net)
Xponance Inc. Sells 130 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
Read Xponance Inc. Sells 130 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) at Defense World
Read more
2022-12-15 (genengnews.com)
Wide Shot: Jacob Glanville Pursues Broad-Spectrum Vaccines vs. Pandemics
In an exclusive interview with GEN Edge, Centivax CEO and president Jacob Glanville, PhD, discusses Centivax’s effort to develop broad-spectrum vaccines for mutating viruses, and the challenges the company has encountered developing them.
Read more